Logo
Login
$RXRX
$4.05 +$0.25 (6.58%) Close

Company Executives

$RXRX Management Team

Dr. Christopher Gibson

Chairman of the Board

Age 42
Compensation $8.500M USD
Sex Male

Dr. Robert Hershberg

Lead Independent Vice Chairman of the Board

Age 62
Compensation $316.5K USD
Sex Male

Mr. Ben Taylor

Chief Financial Officer

President of Recursion UK

Age 48
Compensation $8.172M USD
Sex Male

Dr. Najat Khan

President

Chief Executive Officer

Age 42
Compensation $9.195M USD
Sex Female

Board of Directors

From the proxy statement filed Apr 30, 2026
Directors
10
serving now
Independent
8 of 8
stated in the proxy; 2 not stated
Average tenure
6.9 years
from year joined
CEO also chairs the board
No
Christopher Gibson
Director Age On board Independent Committees Other public boards 2025 pay Source
Najat Khan
CEO
 42 2024
2 years
 Not stated
Strategic Transactions and Finance
None stated Paid as CEO
Franziska Michor
43 2024
2 years
 Independent
Technology
None stated Not stated
Zachary Bogue
50 2018
8 years
 Independent
Compensation
None stated Not stated
Blake Borgeson
44 2013
13 years
 Independent
Audit Nominating & Governance
None stated Not stated
Namandjé Bumpus
45 2025
1 year
 Independent
Nominating & Governance Technology
None stated Not stated
Zavain Dar
37 2016
10 years
 Independent
Audit Technology
None stated $308,160
Robert Hershberg
63 2020
6 years
 Independent None stated Adaptive Biotechnology, AtaiBeckley Not stated
Dean Y. Li
64 2013
13 years
 Independent None stated None stated Not stated
Elaine Sun
55 2025
1 year
 Independent
Compensation
None stated $741,570
Christopher Gibson Leaving at the meeting
Board chair
 43 2013
13 years
 Not stated
Technology
Pacific Biosciences of California, Inc. Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 30, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans